Summary: Comedian Shane Mauss interviews Allison Wilens of MAPS Public Benefit Corporation (MPBC) about the process of developing clinical trials of MDMA-assisted psychotherapy as a treatment for multiple mental health issues. Wilens speaks about MAPS’ recent meeting with U.S. Food and Drug Administration (FDA) about the progress of research into MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). “Completing the Phase 2 program and moving to this next phase is significant because it means that MDMA has been acknowledged as safe enough to pursue as a treatment, to investigate if it can work for PTSD,” explains Wilens.
Originally appearing here.
Allison Wilens is a Clinical Study Associate at MAPS Public Benefit Corporation. This week we talk about MDMA-assisted psychotherapy for PTSD and the process behind developing clinical trials.
